Enovis (ENOV) to Release Quarterly Earnings on Thursday

Enovis (NYSE:ENOV) is scheduled to be announcing its earnings results before the market opens on Thursday, May 2nd. Analysts expect the company to announce earnings of $0.50 per share for the quarter. Enovis has set its FY 2024 guidance at 2.500-2.650 EPS and its FY24 guidance at $2.50-$2.65 EPS.Individual that are interested in registering for the company’s earnings conference call can do so using this link.

Enovis (NYSE:ENOV) last announced its quarterly earnings data on Thursday, February 22nd. The company reported $0.79 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.76 by $0.03. The firm had revenue of $455.00 million during the quarter, compared to the consensus estimate of $444.34 million. Enovis had a positive return on equity of 3.84% and a negative net margin of 1.95%. The business’s revenue for the quarter was up 11.2% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.72 EPS. On average, analysts expect Enovis to post $3 EPS for the current fiscal year and $3 EPS for the next fiscal year.

Enovis Stock Up 1.3 %

Shares of NYSE:ENOV opened at $56.17 on Thursday. The company has a market capitalization of $3.08 billion, a PE ratio of -92.10 and a beta of 1.97. The company has a debt-to-equity ratio of 0.14, a current ratio of 2.43 and a quick ratio of 1.16. The business has a fifty day moving average price of $60.10 and a two-hundred day moving average price of $55.47. Enovis has a 1 year low of $43.04 and a 1 year high of $66.14.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on the company. Wells Fargo & Company upped their price objective on Enovis from $73.00 to $79.00 and gave the company an “overweight” rating in a research note on Friday, February 23rd. Stephens began coverage on Enovis in a research note on Tuesday, February 13th. They issued an “overweight” rating and a $72.00 price objective for the company. UBS Group began coverage on Enovis in a research report on Monday, January 22nd. They set a “buy” rating and a $75.00 price target on the stock. William Blair began coverage on Enovis in a research report on Wednesday, January 3rd. They set an “outperform” rating on the stock. Finally, Canaccord Genuity Group upped their price target on Enovis from $73.00 to $75.00 and gave the company a “buy” rating in a research report on Friday, February 23rd. Eight research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $75.43.

About Enovis

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.